Perilipin-5 as a potential new biomarker in patients with liver disease and impaired De Ritis ratio

Basit Öğe Kaydı
dc.authorwosidŞahin, İbrahim/HHY-8303-2022
dc.contributor.authorŞahin, İbrahim Ethem
dc.contributor.authorHacıoğlu, Ceyhan
dc.contributor.authorDavran, Fatih
dc.contributor.authorAlpay, Merve
dc.date.accessioned2023-07-26T11:54:08Z
dc.date.available2023-07-26T11:54:08Z
dc.date.issued2021
dc.departmentDÜ, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Tıbbi Biyokimya Ana Bilim Dalıen_US
dc.description.abstractPurpose: Liver dysfunctions are one of the most prevalent and deadly diseases worldwide. The De Ritis ratio, which is obtained by proportioning serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT), has been suggested to be a precious marker to assess the prognosis of liver diseases. This study was to investigate the relationship between perilipin 5 (PLIN5) levels and De Ritis ratio in patients with liver disease. Materials and Methods: There were 3 groups: control (Group1; n=20), hepatic patients with normal De Ritis ratio (Group2; n=35) and hepatic patients with impaired De Ritis ratio (Group3; n=35). De Ritis rates of all patients were determined according to the serum aspartate aminotransferase (AST)/serum alanine aminotransferase (ALT) results. Additionally, PLIN5 was spectrophotometrically analyzed from serum samples. Results: There is no significant difference between the groups in terms of age and gender. PLIN5 levels increased by 2.6 and 3.8 times in Group2 and Group3, respectively. De Ritis ratio was significantly increased in the Group3 compared the control, and enhanced PLIN5 levels was correlated with De Ritis ratio in the Group3. There was a significant positive correlation between De Ritis ratio and PLIN5 levels. Conclusion: PLIN5 levels together with De Ritis rate in liver patients may be used as a prognostic marker. Furthermore, this relationship could be a useful method in the follow-up of liver diseases.en_US
dc.identifier.doi10.17826/cumj.975899
dc.identifier.endpage1326en_US
dc.identifier.issn2602-3032
dc.identifier.issn2602-3040
dc.identifier.issue4en_US
dc.identifier.startpage1321en_US
dc.identifier.trdizinid468353en_US
dc.identifier.urihttps://doi.org/10.17826/cumj.975899
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/468353
dc.identifier.urihttps://hdl.handle.net/20.500.12684/12736
dc.identifier.volume46en_US
dc.identifier.wosWOS:000728748600001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.institutionauthorŞahin, İbrahim
dc.institutionauthorEthemHacıoğlu, Ceyhan
dc.institutionauthorDavran, Fatih
dc.institutionauthorAlpay, Merve
dc.language.isoenen_US
dc.publisherCukurova Univ, Fac Medicineen_US
dc.relation.ispartofCukurova Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz$2023V1Guncelleme$en_US
dc.subjectDe Ritis Ratio; Perilipin5; Liver Damage; Ast; Alten_US
dc.subjectInsulin-Resistance; Fatty-Acid; Enzymes; Proteinen_US
dc.titlePerilipin-5 as a potential new biomarker in patients with liver disease and impaired De Ritis ratioen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
12736.pdf
Boyut:
321.93 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu